Genentech will permanently eliminate 143 positions at its South San Francisco headquarters, marking the third wave of workforce reductions at the pioneering biotech firm in just over a year.
The layoffs, disclosed in a May 29 state filing under California’s WARN Act, arrive even as parent company Roche posted a $16 billion profit last year. The cuts sweep across multiple divisions: engineers, analysts, directors, senior directors, and assorted managers all appear on the notice. Teams devoted to artificial intelligence, machine learning, social media, facilities operations, and clinical supplies all lost staff. Every affected employee worked out of the company’s 1 DNA Way campus, and the filing classifies all separations as permanent.
A company spokesperson, Nadine Pinell, framed the move not as a belt-tightening measure but as a “strategic workforce planning exercise.” She described the decision as part of routine organizational recalibration. “Periodically, adjustments and decisions are necessary regarding the right buildup of our workforce within our company’s various functions,” Pinell wrote.
Those adjustments have now become a recurring pattern. Genentech cut 436 jobs in April 2024, then followed up with another 93 layoffs that August. The broader biotech sector has absorbed waves of job losses over the past two years, though much of that pain concentrated among smaller, cash-strapped startups nearing the end of their financial runway. Genentech, by contrast, operates as a cornerstone asset inside a pharmaceutical giant. Roche maintains roughly 2,000 open positions across its global enterprise, and Pinell confirmed that departing workers will receive severance packages, continued benefits, and career transition support.
Genentech’s roots in the Bay Area run deeper than virtually any other life sciences company. Founded in 1976 by UCSF researcher Dr. Herbert Boyer and a venture capitalist, the firm claims the title of the world’s first biotechnology company. Roche’s $46.8 billion acquisition in 2009 allowed the subsidiary to preserve its own leadership structure, board, and South San Francisco base. Today, the company reports around 11,900 employees and 270 active clinical trials, with market-approved treatments spanning targeted cancer therapies, multiple sclerosis drugs, and dozens of other medicines.
The latest reduction signals that even profitable, deeply entrenched biotech players continue to reshape their workforces as strategic priorities shift.
